Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.460 CausalMutation disease CGI
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.460 CausalMutation disease CLINVAR
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.460 AlteredExpression disease BEFREE Using human breast adenocarcinoma MCF-7 cells and immortalized human mammary epithelial MCF-10A cells, we determined the effects of 6-NC on the expression of p53 protein and its direct downstream target cyclin-dependent kinase inhibitor p21(Cip1) as well as on the cell cycle progression. 17678638 2007
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.460 Biomarker disease BEFREE Also, the method was applied to the assay of p53 in human plasma sample and normal and malignant cell line lysates such as (L929 normal cell Line from mouse C3H (L929), colon cancer cell-HCT, prostate cancer cell line PC-3, and human breast adenocarcinoma cell line-MCF7). 28774804 2017
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.460 Biomarker disease BEFREE We have investigated the relationship between the development of tumor resistance towards the cytotoxic action of tumor necrosis factor-alpha (TNF) and p53 function, using the TNF-sensitive MCF7 human breast adenocarcinoma cell line and two TNF-resistant sublines, MCF7/R-A1 and MCF7/Adr. 9419972 1997
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.460 AlteredExpression disease BEFREE Activation of BP in A-549 lung carcinoma and MCF-7 breast adenocarcinoma cell lines containing wild-type p53 was followed by an increase in p53 protein expression. alpha-Naphthoflavone, an inhibitor of cytochrome P450 (CYP)1A1, decreased both the formation of diolepoxide metabolites and the p53 response. 7554063 1995
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.460 AlteredExpression disease BEFREE H19 overexpression in breast adenocarcinoma stromal cells is associated with tumor values and steroid receptor status but independent of p53 and Ki-67 expression. 9811352 1998
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.460 GeneticVariation disease BEFREE In the present study, we compared the dynamics and composition of microtubules in cell lines derived from the human breast adenocarcinoma MCF-7 containing either the wild-type p53 (wt-p53; MN1) or a dominant-negative variant of p53 gene (mut-p53; MDD2). 12771997 2003
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.410 CausalMutation disease CGI
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.410 Biomarker disease BEFREE Regarding molecular factors, all driver mutations in lung adenocarcinoma had a favorable effect (EGFR, HR 0.53, 95%CI 0.31-0.89; ALK, HR 0.28, 95%CI 0.12-0.66; KRAS, HR 0.65, 95%CI 0.47-0.92), triple negative status predicted poor prognosis in breast adenocarcinoma (HR 2.04, 95%CI 1.13-3.69), while no effect of BRAF/NRAS mutations was demonstrated in melanoma BMs. 30989623 2019
Entrez Id: 5290
Gene Symbol: PIK3CA
PIK3CA
0.410 AlteredExpression disease BEFREE Biological screening revealed that the newly synthesized compounds inhibit PI3Kα activity in human colon adenocarcinoma (HCT-116), breast adenocarcinoma (MCF-7), and breast carcinoma (T47D) cell lines. 29651943 2018
Entrez Id: 5290
Gene Symbol: PIK3CA
PIK3CA
0.410 CausalMutation disease CLINVAR
Entrez Id: 5290
Gene Symbol: PIK3CA
PIK3CA
0.410 CausalMutation disease CGI
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.410 CausalMutation disease CLINVAR
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.400 CausalMutation disease CGI
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.400 GeneticVariation disease BEFREE The incidence of topoisomerase II-alpha genomic alterations in adenocarcinoma of the breast and their relationship to human epidermal growth factor receptor-2 gene amplification: a fluorescence in situ hybridization study. 15891995 2005
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.400 Biomarker disease BEFREE Spheroids of HER2-Positive Breast Adenocarcinoma for Studying Anticancer Immunotoxins In Vitro. 28461972 2019
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.400 Biomarker disease BEFREE Fifty patients with typical infiltrating ductal adenocarcinoma of the breast were studied for amplification of the c-erb B-2 (neu/HER-2) oncogene within the tumor DNA. 1967929 1990
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.400 Biomarker disease BEFREE We report the case of an 82-year-old male patient with a > 8-year history of prostate cancer (PrCa), who developed breast adenocarcinoma (BrCa) (Ki-67+ and negative for ER, PR, PSA and HER2/neu) after prolonged (approximately 7-year) anti-androgen (flutamide) monotherapy for locally advanced PrCa. 15154626 2004
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.400 Biomarker disease BEFREE Patients ≥ 18 years of age with histologically-confirmed HER2-positive adenocarcinoma of the breast (clinical T1-T3, N0-N2, M0), normal left ventricular ejection fraction, and adequate organ function received trastuzumab 6 mg/kg intravenous (I.V.) 25640059 2015
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.400 Biomarker disease BEFREE Fluorescence in situ hybridization (FISH) as primary methodology for the assessment of HER2 Status in adenocarcinoma of the breast: a single institution experience. 18043283 2007
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.400 Biomarker disease BEFREE This observational study was conducted in patients with HER2-positive breast adenocarcinoma ≤1.5 cm who received trastuzumab-based adjuvant treatment in clinical practice. 26103952 2015
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.400 Biomarker disease BEFREE Twenty-six women with newly diagnosed stage II to III histologically or cytologically proven adenocarcinoma of the breast with negative HER2 status were enrolled. 28579139 2017
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.400 Biomarker disease BEFREE We found that recombinant protein 4D5scFv-miniSOG exerts a highly specific photo-induced cytotoxic effect on HER2/neu-positive human breast adenocarcinoma SK-BR-3 cells (IC50= 160 nM). 24312153 2013
Entrez Id: 2064
Gene Symbol: ERBB2
ERBB2
0.400 AlteredExpression disease BEFREE The influence of polysomy 17 on HER2 gene and protein expression in adenocarcinoma of the breast: a fluorescent in situ hybridization, immunohistochemical, and isotopic mRNA in situ hybridization study. 16096413 2005